181 related articles for article (PubMed ID: 23053885)
21. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.
Sample C; Bailey RJ; Todoruk D; Sadowski D; Gramlich L; Milan M; Cherry R; Ma M; Lalor E; McKaigney J; Sherbaniuk R; Matic K; Switzer C; Fedorak RN
Can J Gastroenterol; 2002 Mar; 16(3):165-70. PubMed ID: 11930194
[TBL] [Abstract][Full Text] [Related]
23. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Rutgeerts P; Feagan BG; Lichtenstein GR; Mayer LF; Schreiber S; Colombel JF; Rachmilewitz D; Wolf DC; Olson A; Bao W; Hanauer SB
Gastroenterology; 2004 Feb; 126(2):402-13. PubMed ID: 14762776
[TBL] [Abstract][Full Text] [Related]
24. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
25. Use of infliximab in pediatric patients with inflammatory bowel disease.
Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
[TBL] [Abstract][Full Text] [Related]
26. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
Kugathasan S
J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S40-3. PubMed ID: 11685975
[No Abstract] [Full Text] [Related]
27. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
28. Infliximab dependency in a national cohort of children with Crohn's disease.
Wewer V; Riis L; Vind I; Husby S; Munkholm P; Paerregaard A
J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):40-5. PubMed ID: 16385252
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
[TBL] [Abstract][Full Text] [Related]
30. Long term safety of infliximab.
Schaible TF
Can J Gastroenterol; 2000 Sep; 14 Suppl C():29C-32C. PubMed ID: 11023558
[TBL] [Abstract][Full Text] [Related]
31. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
32. Response to infliximab is related to disease duration in paediatric Crohn's disease.
Lionetti P; Bronzini F; Salvestrini C; Bascietto C; Canani RB; Dé Angelis GL; Guariso G; Martelossi S; Papadatou B; Barabino A
Aliment Pharmacol Ther; 2003 Aug; 18(4):425-31. PubMed ID: 12940928
[TBL] [Abstract][Full Text] [Related]
33. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
35. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
36. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
37. Infliximab and surgical treatment of complex anal Crohn's disease.
Duff S; Sagar PM; Rao M; Dolling S; Sprakes M; Hamlin PJ
Colorectal Dis; 2012 Aug; 14(8):972-6. PubMed ID: 21899707
[TBL] [Abstract][Full Text] [Related]
38. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
39. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
40. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
